Janux Therapeutics (JANX) Expected to Announce Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $13.21 on Thursday. The business has a 50-day moving average price of $13.88 and a two-hundred day moving average price of $21.21. Janux Therapeutics has a 12-month low of $12.12 and a 12-month high of $38.42. The firm has a market cap of $794.58 million, a P/E ratio of -7.86 and a beta of 2.88.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Cantor Fitzgerald dropped their target price on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Piper Sandler lowered their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, January 16th. HC Wainwright reduced their target price on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Barclays lowered their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Thursday, January 22nd. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.08.

Insider Activity

In other news, insider Zachariah Mciver sold 2,714 shares of Janux Therapeutics stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $37,263.22. Following the sale, the insider directly owned 23,286 shares in the company, valued at approximately $319,716.78. This trade represents a 10.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Charles M. Winter sold 2,401 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $32,965.73. Following the transaction, the insider directly owned 77,721 shares in the company, valued at $1,067,109.33. This trade represents a 3.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 22,366 shares of company stock valued at $371,245. 8.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System grew its position in Janux Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares during the last quarter. Nuveen LLC lifted its stake in shares of Janux Therapeutics by 0.8% in the fourth quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after buying an additional 787 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in shares of Janux Therapeutics by 20.0% in the third quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock worth $279,000 after buying an additional 1,905 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Janux Therapeutics by 11.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,866 shares of the company’s stock valued at $551,000 after buying an additional 2,463 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Janux Therapeutics by 3.4% during the fourth quarter. Swiss National Bank now owns 77,100 shares of the company’s stock valued at $1,064,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.